Kwality Pharmaceuticals Ltd.

BSE: 539997

Strong Performer, Under Radar

Download real time

683.35 18.00 (2.71%)

36.13% Fall from 52W High

6,989 BSE Volume

BSE 21 Mar, 2025 3:31 PM (IST)

709.1

Market Cap

Above industry Median

0.8

Beta 1Year

Very Low volatility

Kwality Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Kwality Pharmaceuticals Ltd. on BSE

Load latest

Kwality Pharmaceuticals Ltd.

24 Dec 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Kwality Receives Product Approval For Tamoxifen 20Mg Tablet In South …

BSE India

Kwality receives Product Approval for Tamoxifen 20mg Tablet in South Africa (SAHPRA)

Kwality Pharmaceuticals Ltd.

27 Nov 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Intimation Under Regulation 30(6) Of SEBI (Listing Obligations And Disclosure …

BSE India

Announcement under Regulation 30(6) of SEBI (LODR) Regulations- Schedule of Analyst/ Investor Meeting

Kwality Pharmaceuticals Ltd.

26 Nov 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Kwality Received Its First Biological Product Permission For Manufacturing And …

BSE India

Kwality received its first Biological Product Permission for Manufacturing and Sale of PEGylated - Asparaginase

Kwality Pharmaceuticals Ltd.

06 Nov 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable …

BSE India

KWALITY PHARMA RECEIVED THE APPROVAL FOR LEUPRORELIN ACETATE FOR INJECTABLE SUSPENSION AS A SITE VARIATION FROM GREECE.

Kwality Pharmaceuticals Ltd.

06 Nov 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

NEWSPAPER PUBLICATION OF RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024.

Kwality Pharmaceuticals Ltd.

30 Oct 2024

683.35

2.71%

Board Meeting

Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Outcome for Submission Of Unaudited Financial Results For …

BSE India

Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 ('Listing Regulations'), this is to inform your that Board of Directors in its meeting held today i.e., October 30, 2024, have inter-alia , considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.

Kwality Pharmaceuticals Ltd.

30 Oct 2024

683.35

2.71%

Result

Kwality Pharmaceuticals Ltd - 539997 - Submission Of Unaudited Financial Results For The Quarter And Half …

BSE India

UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024

Kwality Pharmaceuticals Ltd.

22 Oct 2024

683.35

2.71%

Board Meeting

Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Intimation for Consider And Approve The Unaudited Standalone …

BSE India

Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2024.

Kwality Pharmaceuticals Ltd.

11 Oct 2024

683.35

2.71%

Company Update

Kwality Pharmaceuticals Ltd - 539997 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

CERTIFICATE UNDER REG 74(5)

Kwality Pharmaceuticals Ltd.

29 Sep 2024

683.35

2.71%

SAST

Kwality Pharmaceuticals Ltd - 539997 - Closure of Trading Window

BSE India

closure of trading window

No results found

Is Kwality Pharmaceuticals Ltd. worth buying?

56 Votes:

Buy 71.43%

Sell 16.07%

Hold 12.5%